🟢 Recursion Pharmaceuticals jumps 6.3% with Cathie Wood's ARK Invest loading up shares, building on Tempus AI partnership optimism

Recursion Pharmaceuticals is trading at $5.08, up +6.28%, driven by fresh investment from Cathie Wood's ARK Invest and sustained optimism surrounding its expanded partnership with Tempus AI. - Cathie Wood's ARK Invest acquired approximately 1.48 million shares of RXRX on October 6, 2026. - The partnership with Tempus AI, extended through November 2029, includes a license for Recursion’s proprietary TxFM RNA model, enhancing its AI-driven drug discovery platform. - Major indices are also higher, including the Nasdaq Composite which closed higher on Monday and futures rising today, providing a supportive market backdrop.